Pfizer discussed its plans to expand the availability of its COVID-19 vaccine this fall to include children that are 6-months-old to 11-years-old during an on-camera investor conference Tuesday.
Pfizer’s Chief Financial Officer Frank D’Amelio said the company projects to have safety and efficacy data for children 5 to 11-years-old “by the end of September.” Pfizer expects to file the data with the FDA in “early October.”
D’Amelio said that in the weeks following the submission, the company will file similar data for children between the ages of 6 months to 5-years-old. Phase three studies are currently underway for children in those age groups.
Click here to read more.